Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory May 25, 2022Report from Annual General Meeting in Vivesto AB
-
Regulatory May 25, 2022Interim report for the period January 1, 2022 – March 31, 2022
-
Non Regulatory May 18, 2022Invitation to presentation of Vivesto’s Q1 report 2022 on May 25
Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program